- Details
- Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...
|
- Details
- Alicia Morgans and Michael Brooks discuss a recent manuscript entitled, “Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-years After Radical Prostatectomy”. Dr. Brooks goes into depth on how adverse pathology correlates with long-term prostate cancer outcomes. They also discuss active surveillance for low-risk patients and how to stratify th...
|
- Details
- Alicia Morgans and Eric Klein discuss two papers that involve a unique cohort of patients with early-stage prostate cancer. Dr. Klein details the use of the Oncotype GPS score to stratify patients and determine who is safe for active surveillance. They also discuss how to use MRI histology, adverse pathology, and genomic profiling systems together. They discuss advising clinicians on how to start...
|
- Details
- In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...
|
- Details
- Alicia Morgans is joined by Felix Feng to discuss an AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition of ADT. This AI-derived predictive bioma...
|
- Details
- Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...
|
- Details
- This UroToday journal presented by Zachary Klaassen and Christopher J.D. Wallis discusses Version 1 2022 Prostate Cancer guidelines discussing the comparison of treatment options for localized disease followed by a discussion on local therapies and finally disease monitoring. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toront...
|
- Details
- In this UroToday Journal Club video, Drs Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication "Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer". This work aimed to assess the association between treatment approach, functional outcomes, patient expectations, and treat...
|
- Details
- Paul Nguyen and Alan Pollack join Alicia Morgans in a discussion on risk prognostication in high-risk prostate cancer. Dr. Nguyen discusses the role of genomics to risk-stratify high-risk prostate cancer patients and the role of Decipher at the time of biopsy. He reviews data from an oral presentation he delivered at the 2021 American Society for Radiation Oncology (ASTRO) annual meeting titled: V...
|
- Details
- In this UroToday Journal Club presentation Christopher Wallis and Zachary Klaassen, continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer. Dr. Christopher Wallis discusses the use of nomograms and the use of Tumor Multigene Molec...
|
